CN1913893A - 改善麻醉恢复的nk－1受体拮抗剂 - Google Patents

改善麻醉恢复的nk－1受体拮抗剂 Download PDF

Info

Publication number
CN1913893A
CN1913893A CNA2005800036680A CN200580003668A CN1913893A CN 1913893 A CN1913893 A CN 1913893A CN A2005800036680 A CNA2005800036680 A CN A2005800036680A CN 200580003668 A CN200580003668 A CN 200580003668A CN 1913893 A CN1913893 A CN 1913893A
Authority
CN
China
Prior art keywords
chemical compound
structural formula
compound
salt
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800036680A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·希克曼
C·E·米斯克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1913893A publication Critical patent/CN1913893A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CNA2005800036680A 2004-01-30 2005-01-06 改善麻醉恢复的nk－1受体拮抗剂 Pending CN1913893A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54069704P 2004-01-30 2004-01-30
US60/540,697 2004-01-30

Publications (1)

Publication Number Publication Date
CN1913893A true CN1913893A (zh) 2007-02-14

Family

ID=34910695

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800036680A Pending CN1913893A (zh) 2004-01-30 2005-01-06 改善麻醉恢复的nk－1受体拮抗剂

Country Status (14)

Country Link
US (1) US20070155782A1 (enExample)
EP (1) EP1713479A1 (enExample)
JP (1) JP2007519701A (enExample)
KR (1) KR100880391B1 (enExample)
CN (1) CN1913893A (enExample)
AU (1) AU2005216706B2 (enExample)
BR (1) BRPI0507325A (enExample)
CA (1) CA2554823A1 (enExample)
IL (1) IL176830A0 (enExample)
MX (1) MXPA06007964A (enExample)
NO (1) NO20062965L (enExample)
RU (1) RU2337685C2 (enExample)
WO (1) WO2005082366A1 (enExample)
ZA (1) ZA200605149B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548236A (en) 2004-01-30 2010-02-26 Pfizer Prod Inc Compositions comprising (2S.3S) (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-alkyl-2-methoxy-benzyl)-amine derivatives
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
RU2489765C1 (ru) * 2012-01-10 2013-08-10 Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") Способ изготовления газонаполненного разрядника
CN114984223B (zh) * 2022-05-31 2023-06-20 中国人民解放军陆军军医大学第二附属医院 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用
AT527172A1 (de) * 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US540644A (en) 1895-06-11 del yalle
US540897A (en) 1895-06-11 Harold f
SK278788B6 (sk) 1991-05-31 1998-02-04 Pfizer Inc. Chinuklidínové deriváty, spôsob ich prípravy a pou
US5393762A (en) 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6255320B1 (en) 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
CA2448722A1 (en) 2001-07-20 2003-02-06 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses

Also Published As

Publication number Publication date
JP2007519701A (ja) 2007-07-19
IL176830A0 (en) 2006-10-31
US20070155782A1 (en) 2007-07-05
BRPI0507325A (pt) 2007-07-03
RU2006126828A (ru) 2008-03-10
AU2005216706B2 (en) 2007-11-29
AU2005216706A1 (en) 2005-09-09
MXPA06007964A (es) 2007-01-26
RU2337685C2 (ru) 2008-11-10
CA2554823A1 (en) 2005-09-09
WO2005082366A8 (en) 2005-12-15
KR100880391B1 (ko) 2009-01-30
ZA200605149B (en) 2007-11-28
NO20062965L (no) 2006-07-21
WO2005082366A1 (en) 2005-09-09
EP1713479A1 (en) 2006-10-25
KR20060127934A (ko) 2006-12-13

Similar Documents

Publication Publication Date Title
CN1946403A (zh) 氟班色林在治疗经前期及其他女性的性功能障碍中的用途
CN1354658A (zh) 化合物作为抗菌剂的新用途
CA2332253A1 (en) Combination therapy for treatment of depression
CN101073563A (zh) 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
CN1686117A (zh) 左旋奥硝唑在制备抗厌氧菌感染药物的应用
CN1913893A (zh) 改善麻醉恢复的nk－1受体拮抗剂
CN1117267A (zh) 含苯并咪唑类驱肠虫药和亚甲二氧苯基类化合物的增效组合物
CN1225011A (zh) 含有1－甲基碳青霉烯衍生物作为活性成分的抗幽门螺杆菌组合物
CN1809359A (zh) 用于治疗抑郁症和/或焦虑症的包含帕罗西汀和2－(s) －(4－氟－2－甲基－苯基)－哌嗪－1－羧酸[1－(r) －(3, 5－二－三氟－2－甲基-苯基) －乙基]甲基酰胺的联合药物
CN1230165C (zh) 治疗呼吸疾病的芳基(或杂芳基)氮杂茂基甲醇衍生物
CN1660098A (zh) 含有盐酸西替利嗪的口服药物组合物
CN1468602A (zh) 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用
HK1100640A (en) Nk-1 receptor antagonists anesthesia recovery
CN1917903A (zh) 止吐剂和脑啡肽酶抑制剂的新组合
CN1634062A (zh) 盐酸纳美芬鼻腔给药制剂
CN1615871A (zh) 加替沙星静脉输注制剂及其制备方法
CN107427508B (zh) 异喹啉衍生物用于糖尿病伤口愈合的用途
CN1323662C (zh) 含有氨溴索和厄多司坦或乙酰半胱氨酸的药物组合物及其应用
CN1276753C (zh) 用于治疗类阿片依赖性的吡啶－2－基－甲胺衍生物
CN1468094A (zh) 含有依匹期汀及假麻黄碱的新药物组合物
CN115737648B (zh) 二苯甲基哌嗪类化合物在治疗包虫病中的应用
CN1726915A (zh) 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
CN1616102A (zh) 治疗感冒的复方干混悬剂及其处方和制备方法
CN1883503A (zh) 用于治疗胃病的含有抗溃疡药和粘膜保护剂的药物组合物
CN1652762A (zh) 抗鼻病毒活性剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1100640

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070214

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1100640

Country of ref document: HK